Bobcat339
Bobcat339 is a potent and selective cytosine-based inhibitor of TET enzyme, with IC50s of 33 μM and 73 μM for TET1 and TET2, respectively. Bobcat339 is useful to the field of epigenetics and serves as a starting point for new therapeutics that target DNA methylation and gene transcription[1].
Product Specifications
CAS Number
2280037-51-4
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
DNA Methyltransferase; TET Protein
Type
Reference compound
Related Pathways
Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/bobcat339.html
Purity
99.44
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
NC1=NC(N(C2=CC=CC(C3=CC=CC=C3)=C2)C=C1Cl)=O
Molecular Formula
C16H12ClN3O
Molecular Weight
297.74
Precautions
H302, H315, H319, H335
References & Citations
[1]Chua GNL, et, al. Cytosine-Based TET Enzyme Inhibitors. ACS Med Chem Lett. 2019 Jan 31; 10 (2) : 180-185.|[2]Weirath NA, et al. Small Molecule Inhibitors of TET Dioxygenases: Bobcat339 Activity Is Mediated by Contaminating Copper (II) . ACS Med Chem Lett. 2022 Apr 21;13 (5) :792-798.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C, 3 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
TET1; TET2
Citation 01
Aquaculture. 2023: 739234.|Br J Pharmacol. 2024 Oct;181 (20) :3886-3907.|Brain Sci. 2023 Apr 10;13 (4) :644.|EMBO Mol Med. 2025 Oct;17 (10) :2809-2826.|Eur J Pharmacol. 2024 Aug 23:176931.|J Exp Clin Cancer Res. 2025 Jul 15;44 (1) :206.|Research Square Print. 2023 Mar 14.|Research Square Print. November 29th, 2022.|Bioelectrochemistry. 2023 Aug:152:108433.|Cancers (Basel) . 2022 Jun 16;14 (12) :2983.|Cell Death Dis. 2024 Jun 1;15 (6) :387.|Clin Epigenetics. 2024 Oct 2;16 (1) :136.|Clin Sci. 2023 Aug 31;137 (16) :1265-1283.|Environ Sci Technol. 2021 Mar 2;55 (5) :3144-3155.|J Clin Invest. 2023 Oct 16;133 (20) :e170173.|J Pharm Biomed Anal. 2021 Sep 5:203:114228.|Mol Pain. 2022 Apr;18:17448069221143671.|Nat Metab. 2025 Jul;7 (7) :1344-1357.|Neuropharmacology. 2024 Feb 15:244:109799.|Sci Total Environ. 2024 Apr 1:919:170905.|Theranostics. 2021 Jun 11;11 (16) :7640-7657.
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
K0918902 1.0 µg DNA
GTPBP1 sgRNA CRISPR Lentivector (Human) (Target 1)
Sign In for Pricing
View Details